Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$

Name	of entity	
Stem	ify Limited (Company)	
ABN 20 00	09 256 535	
We (t	he entity) give ASX the following	information.
	t 1 - All issues ust complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	5,000,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares at an issue price of 2 cents per share

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$100,000 at an issue price of 2 cents per
		share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of shares following shareholder approval being obtained at the Company's 2019 Annual General Meeting to allow director participation in a placement. Funds raised from the issue of the shares will be used by the Company for the marketing and sale of the Company's education focused products including MyStemKits curriculum and 3D printer hardware.
6a	Is the entity an ⁺ eligible entity	Voc
0a	that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29 November 2019
6c	Number of *securities issued without security holder approval under rule 7.1	N/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
_			
6e	Number of *securities issued with security holder approval	5,000,000	
	under rule 7.3, or another specific security holder approval (specify date of meeting)	Approved by sharehold on 29 November 2019.	ders at 2019 AGM held
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6 ~	If tangunities issued under rule	NI / A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under	N / A	
OII	rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
_			
7	⁺ Issue dates	27 December 2019	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		<u> </u>	T . 25
		Number	⁺ Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	156,972,435	Fully paid ordinary shares

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

N. 1	- a1
Number	+Class
464,445	Executive performance rights
124,444	Founder performance rights
194,461	Employee performance rights
311,109	Advisor options exercisable at \$6.75, expiring 22 December 2019
11,112	Unquoted options exercisable at \$4.50, expiring 27 June 2021
11,112	Unquoted options exercisable at \$4.50, expiring 8 August 2021
11,112	Unquoted options exercisable at \$4.50, expiring 23 August 2021
35,556	Unquoted options exercisable at \$4.05, expiring 20 November 2020
111,112	Unquoted options exercisable at \$3.375, expiring 30 June 2021
133,334	Unquoted options exercisable at \$2.70, on or before 28 August 2021
30,000,000	Advisor options exercisable at \$0.025, expiring 31 December 2022
37,500,000	Conversion Securities exercisable at A\$0.05 and expiring 30 June 2023
7,500,000	Unquoted options exercisable at \$0.05, expiring 30 June 2020

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			
11/11			

Appendix 3B Page 4 04/03/2013

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Part	Part 2 - Pro rata issue			
11	Is security holder approval required?			
12	Is the issue renounceable or non-renounceable?			
13	Ratio in which the *securities will be offered			
14	⁺ Class of ⁺ securities to which the offer relates			
15	⁺ Record date to determine entitlements			
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?			
17	Policy for deciding entitlements in relation to fractions			
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.			
19	Closing date for receipt of acceptances or renunciations			

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by chrough a broker)?	
33	⁺ Issue	e date	
		Quotation of securitie complete this section if you are applying	
34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part 1	
(b)			the escrowed period, partly paid securities that become fully paid, striction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	at have ticked box 34(a)	
Addit	ional s	securities forming a new cla	ss of securities
Tick to docume		te you are providing the information	or
35			urities, the names of the 20 largest holders of the number and percentage of additional *securities
36		If the *securities are *equity se *securities setting out the numb 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	curities, a distribution schedule of the additional er of holders in the categories
37		A copy of any trust deed for the	additional ⁺ securities

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Entiti	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	*Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Print name:	Maggie Niewidok		
Sign here:	Company secretary	Date: .	27 December 2019

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	588,868,914	
Add the following:	139,500,000 (16 August 2019)	
 Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval Number of partly paid *ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	51,475 (13 September 2019) 5,000,000 (27 December 2019)	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	546,447,954 (45 to 1 consolidation completed on 12 August 2019)	
"A"	156,972,435	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	23,545,865
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil
Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	0
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	23,545,865
Note: number must be same as shown in Step 2	
Subtract "C"	0
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	23,545,865
	[Note: this is the remaining placement capacity under rule 7.1]

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	15,697,243
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	0

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	15,697,243
Note: number must be same as shown in Step 2	
Subtract "E"	0
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	15,697,243
	[Note: this is the remaining placement capacity under rule 7.1A]

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.